AmbioPharm

AmbioPharm, founded in 2005 and headquartered in North Augusta, South Carolina, is a global Contract Development and Manufacturing Organization (CDMO) specializing in peptide manufacturing. The company focuses on developing highly efficient processes for peptide-based Active Pharmaceutical Ingredients (APIs) at scales ranging from small to very large. AmbioPharm serves a diverse clientele, including pharmaceutical companies and biotech firms, providing them with tailored peptide manufacturing solutions. The company operates in the pharmaceutical and biotechnology markets, leveraging its extensive manufacturing capabilities and FDA-inspected facilities to ensure high-quality production standards.

AmbioPharm's business model revolves around offering comprehensive peptide manufacturing services, from development to large-scale production. The company generates revenue through contract manufacturing agreements, where clients pay for the development and production of peptide APIs. This model allows AmbioPharm to handle projects of varying sizes and complexities, making it a versatile partner in the peptide manufacturing industry.

Under the leadership of CEO Brian Gregg, who brings extensive experience from his tenure at Bachem, AmbioPharm continues to drive business and operational growth. The company is committed to diversity and inclusion, promoting a culture that values cooperation with the communities it serves.

Keywords: peptide manufacturing, CDMO, APIs, pharmaceutical, biotechnology, FDA-inspected, large-scale production, contract manufacturing, operational growth, diversity.